Search research articles
Contact Us
Filters
Showing results (61-70 of 87) with videos related to
Page
of 9
Sort By:
Neuro-Oncology
|
April 17, 2018
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma
Benjamin M Ellingson, Dana T Aftab, Gisela M Schwab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 29, 2017
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials
Benjamin M Ellingson, Elizabeth R Gerstner, Marion Smits, et al.
Pigment Cell & Melanoma Research
|
September 13, 2016
Melanoma central nervous system metastases: current approaches, challenges, and opportunities
Justine V Cohen, Hussain Tawbi, Kim A Margolin, et al.
Nature Communications
|
July 10, 2021
Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine
Yasaman Barekatain, Jeffrey J Ackroyd, Victoria C Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2020
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Lakshmi Nayak, Annette M Molinaro, Katherine Peters, et al.
Clinical Chemistry
|
January 29, 2015
Clinical actionability enhanced through deep targeted sequencing of solid tumors
Ken Chen, Funda Meric-Bernstam, Hao Zhao, et al.
Neuro-Oncology Advances
|
September 21, 2022
Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis
Rituraj Upadhyay, Swapnil Khose, Halyna Pokhylevych, et al.
The Lancet. Oncology
|
January 5, 2024
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group
Nathalie L Albert, Norbert Galldiks, Benjamin M Ellingson, et al.
Nature Cancer
|
February 1, 2021
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer
C Allison Stewart, Carl M Gay, Yuanxin Xi, et al.
Neuro-Oncology Advances
|
April 22, 2026
CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas
Shuodan Zhang, Byram H Ozer, Antonio Omuro, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 87) with videos related to
Sort By:
Page
of 9
Neuro-Oncology
|
April 17, 2018
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma
Benjamin M Ellingson, Dana T Aftab, Gisela M Schwab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 29, 2017
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials
Benjamin M Ellingson, Elizabeth R Gerstner, Marion Smits, et al.
Pigment Cell & Melanoma Research
|
September 13, 2016
Melanoma central nervous system metastases: current approaches, challenges, and opportunities
Justine V Cohen, Hussain Tawbi, Kim A Margolin, et al.
Nature Communications
|
July 10, 2021
Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine
Yasaman Barekatain, Jeffrey J Ackroyd, Victoria C Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2020
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Lakshmi Nayak, Annette M Molinaro, Katherine Peters, et al.
Clinical Chemistry
|
January 29, 2015
Clinical actionability enhanced through deep targeted sequencing of solid tumors
Ken Chen, Funda Meric-Bernstam, Hao Zhao, et al.
Neuro-Oncology Advances
|
September 21, 2022
Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis
Rituraj Upadhyay, Swapnil Khose, Halyna Pokhylevych, et al.
The Lancet. Oncology
|
January 5, 2024
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group
Nathalie L Albert, Norbert Galldiks, Benjamin M Ellingson, et al.
Nature Cancer
|
February 1, 2021
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer
C Allison Stewart, Carl M Gay, Yuanxin Xi, et al.
Neuro-Oncology Advances
|
April 22, 2026
CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas
Shuodan Zhang, Byram H Ozer, Antonio Omuro, et al.
Page
of 9